---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-046267"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:09:28.732054+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech enters $39.9M secured convertible loan with AlpineBrook; conversion at $0.08/share

## Summary
- Loan of $39,922,134 refinances existing notes and provides $350,000 new cash for operations.
- Convertible at $0.08 per share; 12% interest, one-year maturity, with 20% change-of-control premium.
- Lender issued warrant for up to 3x principal/conversion price shares at $0.08, ten-year term.
- Company must increase authorized shares to allow conversion/warrant exercise; board size fixed at nine.
- NKGen has limited cash and continues seeking additional funding; security includes IP and 65% of NKGen Korea.

## SEC filing metadata
- accession: 0001213900-26-046267
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/0001213900-26-046267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/ea0286919-8k_nkgen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-046267
- JSON: https://secwatch.observer/filing/0001213900-26-046267.json
- Plain text: https://secwatch.observer/filing/0001213900-26-046267.txt

## Source-grounded claims
- claim_id: 5dbf7523b048b6affcb5acb7d9983b32b74f01f1
  claim: NKGen Biotech, Inc. incurred convertible notes of $39,922,134.22 with AlpineBrook Capital GP I Limited at 12% per annum maturing one-year anniversary of the closing date.
  evidence_excerpt: Capital GP I Limited (the “Lender”). Background Pursuant to the Loan Agreement, the Lender agreed to extend a secured convertible loan in the aggregate principal amount of $39,922,134.22 (the “Convertible Loan”) to the Borrowers. The Convertible Loan refinances and replaces the following existing indebtedness of the Borrowers to the Lender and East West Bank
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/0001213900-26-046267-index.htm
- claim_id: 0e6ead8ab4ae03be6758320a3b79ca8a3854ba51
  claim: NKGen Biotech, Inc.: Amended Bylaws Section 4.1 to set maximum authorized number of directors at nine, changing from no specified number (effective 2026-04-15).
  evidence_excerpt: The Bylaws Amendment amends and restates Section 4.1 of the Amended and Restated Bylaws of the Company (the “Bylaws”) to provide that the maximum authorized number of directors shall be nine (9).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/0001213900-26-046267-index.htm
- claim_id: f812b954c64ddaf331165a2180f83d8dca301cf4
  claim: NKGen Biotech, Inc. entered into Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited valued at $39,922,134.22 (effective 2026-04-15).
  evidence_excerpt: “NKGen OpCo,” and together with the Company, the “Borrowers”), entered into a Secured Convertible Loan Agreement (the “Loan Agreement”) with AlpineBrook Capital GP I Limited (the “Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/0001213900-26-046267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.